Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

NCT05669950 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05669950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 19, 2022
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia